Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 –STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium...
Year: 2025
MDCE’s Infinite Auctions Announces Fall Flash Auction Featuring Jordan, LeBron, and Brady Amid AI Research Momentum
MESA, AZ / ACCESS Newswire / October 13, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a diversified company advancing...
Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis
Phase 1 trial to investigate novel multi-specific HB2198 to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20...
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and...
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform...
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis,...
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
Appointment adds three decades of financial and operational leadership to Soleno’s BoardREDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) --...
Connect Appoints Tre Braquet as Chief Brand & Engagement Officer
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Connect, a premier nonprofit organization in San Diego’s innovation ecosystem dedicated to...
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings
- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim...
Immutep Announces Successful Completion of FDA Project Optimus Requirements
Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License Applications (BLA)Registrational...
Apyx Medical Corporation Submits FDA 510(k) for Device Label Expansion of AYON Body Contouring System™ for Power Liposuction
Initiated Nationwide Commercial Launch of AYON in September The Company is Hosting a Virtual Key Opinion Leader Event to Discuss...
Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias
ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in...
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M...
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast...
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
Second year proceeds granted following FDA review of annual performance progress report on Phase 3 SELVA single-arm, baseline-controlled trial; up...
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapiesCLEVELAND, Oct. 13,...
Kraig Biocraft Laboratories Announces Selective Breeding Advancement, Significantly Increasing Both Spider Silk Production Throughput and Hybrid Vigor
ANN ARBOR, Mich., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company", “Kraig” or "Kraig Labs"),...
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn.,...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and...
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests...